(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Low testosterone levels may increase the risk of higher-grade “extreme” progression of prostate cancer among men enrolled in active surveillance (AS), according to a study published online Feb 24 in ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

Pfizer (PFE) announced on Thursday that its cancer drug regimen, Talzenna plus Xtandi, met the primary endpoint in a Phase 3 trial for a new indication in prostate cancer. Xtandi, marketed by Pfizer ...

Results challenge view that high testosterone fuels prostate cancer growth ...

Pfizer reported positive topline results in its phase three study of talazoparib in combination with enzalutamide to treat metastatic hormone-sensitive prostate cancer. The study met its primary ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group From March 2021 to August 2022, 669 patients were ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...